false 0001106644 CN 0001106644 2024-12-22 2024-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 22, 2024

 

CHINA PHARMA HOLDINGS, INC. 

(Exact name of Registrant as specified in charter)

 

Nevada   001-34471   73-1564807
(State or other jurisdiction   (Commission File No.)   (IRS Employer
of Incorporation)       Identification No.)

 

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China 570216

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +86 898-6681-1730 (China)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CPHI   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On December 22, 2024, China Pharma Holdings, Inc. (the “Company”) held its annual stockholders’ meeting for the fiscal year ended December 31, 2023 (the “Annual Meeting”). Holders of 9,688,133 shares of the Company’s common stock were present in person or by proxy at the Annual Meeting, representing approximately 52% of the total outstanding shares of common stock and therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Annual Meeting as of the record date of November 1, 2024.

 

The final voting results for the matters submitted to a vote of stockholders at the meeting are as follows.

 

  1. A proposal to elect five director nominees to our Board of Directors:

 

Independent Director’s Name   Votes For   Votes Withheld
Zhilin Li   9,369,099   19,508
Heung Mei Tsui   9,369,099   19,508
Gene Michael Bennett   9,368,708   19,899
Yingwen Zhang   9,368,681   19,926
Baowen Dong   9,368,705   19,902

 

Pursuant to the foregoing votes, Zhilin Li and Heung Mei Tsui were elected to serve as our non-independent directors until the date of the annual shareholders meeting in three years and until their respective successors are duly elected and qualified. Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent directors until the next annual meeting and until their successors are elected and qualified.

 

  2. A proposal to adopt the Amendment No.2 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan:

 

Votes For   Votes Against   Abstentions
9,365,051   23,322   234

 

Pursuant to the foregoing votes, the Amendment No.2 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved and adopted.

 

  3. A proposal to amend the Company’s Articles of Incorporation to effect a reverse stock split, as needed at a ratio between 1:10 and 1:20, such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of common stock for pro rata twenty shares of common stock held:

 

Votes For   Votes Against   Abstentions
9,454,428   233,537   168

 

Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to effect a reverse stock split, as needed at a ratio between 1:10 and 1:20, such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of common stock for pro rata twenty shares of common stock held was approved and adopted. Despite of the foregoing, the Board of the Directors has the discretion to decide if and when to effect the reverse stock split.

 

  4. A proposal to approve, on an advisory and non-binding basis, the compensation of the Company’s named executive officers:

 

Votes For   Votes Against   Abstentions
9,364,170   11,737   12,700

 

Pursuant to the foregoing votes, the compensation of the Company’s named executive officers was approved and adopted.

 

  5. A proposal to select, on a non-binding, advisory basis, the frequency of conducting future stockholder advisory votes on named executive officer compensation:

 

Votes For One Year   Votes For Two Years   Votes For Three Years   Abstentions
255,875   171   9,128,856   3,705

 

Pursuant to the foregoing votes, conducting stockholder advisory votes on named executive officer compensation for every three years was approved and adopted.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 26, 2024

 

  CHINA PHARMA HOLDINGS, INC.
   
  By: /s/ Zhilin Li
    Name: Zhilin Li
    Title: President and
Chief Executive Officer

 

 

 

 

v3.24.4
Cover
Dec. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 22, 2024
Entity File Number 001-34471
Entity Registrant Name CHINA PHARMA HOLDINGS, INC.
Entity Central Index Key 0001106644
Entity Tax Identification Number 73-1564807
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One Second Floor,
Entity Address, Address Line Two No. 17, Jinpan Road
Entity Address, Address Line Three Haikou
Entity Address, City or Town Hainan Province
Entity Address, Country CN
Entity Address, Postal Zip Code 570216
City Area Code 86
Local Phone Number 898-6681-1730
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CPHI
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
China Pharma (AMEX:CPHI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos China Pharma.
China Pharma (AMEX:CPHI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos China Pharma.